| Revenue growth | FY26 Consolidated: ₹332.60 Cr, Standalone: ₹292.14 Cr. |
|---|---|
| Margins | Consolidated PAT margin significantly improved to ₹57.48 Cr in FY26. |
| Demand visibility | Strong via WOAH vaccine bank and African LSD vaccine leadership. |
Growth
Consolidated revenue grew to ₹332.60 Cr in FY26 from ₹311.10 Cr in FY25; PAT rose to ₹57.48 Cr.
Outlook
Expanding Petcare division in India; ongoing R&D for new vaccine ranges; scaling ruminant vaccine accessibility in Africa.
Risks
Expansion risks in African markets (Kenya, Nigeria, Tanzania) and reliance on global vaccine bank tenders.
Earnings Call filed with BSE, NSE: HESTERBIO. Summary written with AI assistance from the document.
Hester Biosciences Ltd: key numbers
- Share price
- ₹2,182.90
- Market cap
- ₹1,857 Cr
- Revenue (annual)
- ₹332.6 Cr
- Net profit (annual)
- ₹55.64 Cr
- P/E (TTM)
- 13.6×Sector 50.4×
- Promoter holding
- 53.73%+0.00% QoQ
- FII holding
- 0.31%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hester Biosciences Ltd
All →Hester Biosciences Promoter Reclassification
Hester Biosciences Limited received shareholder approval to reclassify Mr. Ravin Gandhi and Ms. Bela Gandhi from the 'Promoter' category to the 'Public' category.
Hester Biosciences Annual General Meeting
Hester Biosciences Limited shareholders approved the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public' category via postal ballot.
Hester Biosciences Earnings Call Transcript: Key Takeaways
Hester Biosciences delivered strong standalone Q1 growth with revenues up 14% and profit up 88%. Consolidated profit surged 459% due to an INR 853.49 million exceptional gain from a loan amendment.
Hester Biosciences Q1 FY27 Results: Net Profit ₹96.7 Cr, Up 459.0% YoY
Hester Biosciences Ltd reported revenue from operations of ₹77.2 Cr (-8.2% YoY) and net profit of ₹96.7 Cr (+459.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹96.7 Cr · +459.0% YoY
Hester Biosciences Earnings Call: Key Takeaways
Hester Biosciences reported Q4 and FY26 results with consolidated revenue growth of 22% and substantial PAT increase. Strategy focuses on biologicals, capacity utilization, and African market expansion.
Hester Biosciences Earnings Call: Key Takeaways
Hester Biosciences delivered a strong Q3 FY26 with standalone revenue up 12% and PAT up 140%, driven by robust Poultry Healthcare performance and operational leverage despite Animal Healthcare headwinds.